Format

Send to

Choose Destination
Postgrad Med. 2019 Sep 16:1-8. doi: 10.1080/00325481.2019.1663708. [Epub ahead of print]

Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data.

Author information

1
1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School , Athens , Greece.
2
Department of Nutrition and Diatetics, Harokopio University , Athens , Greece.
3
2nd department of Radliology, University General Hospital "Attikon", National and Kapodistrian University of Athens, Medical School , Athens , Greece.
4
Sleep Study Unit, Department of Psychiatry, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School , Athens , Greece.
5
Laboratory of Biopathology, Aiginition Hospital , Athens , Greece.

Abstract

Objectives: Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION) is a longitudinal ongoing study initiated in 2018 that takes place in the Cognitive Disorders Clinic of Aiginition Hospital of the National and Kapodistrian University of Athens. Its aim is to address several research questions concerning the preclinical and prodromal stage of Alzheimer's disease and explore potential markers for early detection, prediction, and primary prevention of dementia. Methods: We here present the design and the preliminary baseline characteristics of ALBION. The sample of our study consists of people aged over 50 who are concerned about their memory but are cognitively normal (CN) or have mild cognitive deficits. Each participant undergoes an extensive assessment including several demographic, medical, social, environmental, clinical, nutritional, neuropsychological determinants and lifestyle activities. Furthermore, we are collecting data from portable devices, neuroimaging techniques and biological samples (blood, stools, CSF). All participants are assessed annually for a period of 10 years. Results: In total, 47 participants have completed the initial evaluation up to date and are divided in two groups, CN individuals (N = 26) and MCI patients (N = 21), based on their cognitive status. The participants are, on average, 64 years old, 46.3% of the sample is male with an average of 12.73 years of education. MCI patients report more comorbidities and have a lower score in the MMSE test. Regarding APOE status, 2 participants are ε4 homozygotes and 10 ε4 heterozygotes. CSF analyses (Aβ42, Τ-tau, P-tau) revealed no differences between the two groups. Conclusion: The ALBION study offers an opportunity to explore preclinical dementia and identify new and tailored markers, particularly relating to lifestyle. Further investigation of these populations may provide a wider profile of the changes taking place in the preclinical phase of dementia, leading to potentially effective therapeutic and preventive strategies.

KEYWORDS:

ALBION study; biomarkers; preclinical AD

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center